Cellectar Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on June 29, 2023, reporting events occurring on June 28, 2023. Cellectar Biosciences, Inc. (CLRB), a Delaware corporation, presented clinical data from its ongoing study of iopofosine I 131 for the treatment of relapsed or refractory multiple myeloma (MM) at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or updated financial metrics.
Material Changes and Clinical Data
The primary material event is the announcement of clinical data for iopofosine I 131. Key findings include:
- Overall Cohort: In 72 patients (64 evaluable), the drug demonstrated an Overall Response Rate (ORR) of 23%, Clinical Benefit Rate (CBR) of 70%, and Disease Control Rate (DCR) of 92%.
- Optimal Dose Cohort (>60 mCi): Among 28 patients receiving the optimal total administered dose, results showed an ORR of 32%, CBR of 75%, and DCR of 85.7%.
- Refractory Subsets (>60 mCi):
- Triple-class refractory patients (n=18): 46% ORR, median Progression-Free Survival (PFS) of 3.4 months.
- Quad-class refractory patients (n=6): 50% ORR, PFS evaluation ongoing.
- Post-BCMA relapsed/refractory patients (n=6): 50% ORR, median PFS of 3.3 months.
Outlook, Risks, and Adverse Events
Safety Profile: The most common treatment-emergent adverse events were cytopenias, including Grade 3 or 4 thrombocytopenia (62.5%), anemia (62.5%), neutropenia (62.5%), and decreased white blood cell count (50%). Notably, patients did not experience off-target adverse events such as neuropathy, arrhythmia, cardiovascular events, bleeding, ocular toxicities, renal function changes, liver enzyme alterations, or infusion-site reactions.
Treatment Regimen: Patients received up to four 15-minute IV infusions over three months, with doses administered 14 days apart (maximum two cycles), alongside low-dose dexamethasone.
Investor Verification Checklist
- Verify the full statistical analysis of the 64 evaluable patients versus the total 72 enrolled.
- Confirm the ongoing status and expected timeline for Progression-Free Survival (PFS) data in the quad-class refractory subset.
- Review the long-term safety data regarding the high incidence of Grade 3 or 4 cytopenias.
- Check subsequent filings for any updates on regulatory strategy or partnership discussions following the SNMMI presentation.